Skip to main content
. 2022 Mar 26;20(4):670–687. doi: 10.1016/j.gpb.2021.08.016

Figure 6.

Figure 6

ESCC tumor-associated serum metabolites conserved between mice and humans with predictive potential for carcinogenesis

A. Abundance of serum pipecolic acid among control mice (n = 5), 4-NQO-induced mice at the dysplasia stage (4NQO-16wks) (n = 5), and 4-NQO-induced mice at the cancerization stage (4NQO-28wks) (n = 5). B. Abundance of serum pipecolic acid among HCs (n = 34), preoperative ESCC patients (n = 34), and postoperative ESCC patients (n = 34). C. Abundance of serum 1-oleoylglycerol among control mice (n = 5), 4-NQO-induced mice at the dysplasia stage (4-NQO-16wks) (n = 5) and 4-NQO-induced mice at the cancerization stage (4-NQO-28-wks) (n = 5). D. Abundance of serum 1-oleoylglycerol among HCs (n = 34), preoperative ESCC patients (n = 34), and postoperative ESCC patients (n = 34). E. Abundance of serum phosphoric acid among control mice (n = 5), 4-NQO-induced mice at the dysplasia stage (4-NQO-16-wks) (n = 5), and 4-NQO-induced mice at the cancerization stage (4-NQO-28wks) (n = 5). F. Abundance of serum phosphoric acid among HCs (n = 34), preoperative ESCC patients (n = 34) and postoperative ESCC patients (n = 34). ROC curves exhibiting the diagnostic capabilities of serum pipecolic acid (G), 1-oleoylglycerol (H), and phosphoric acid (I) to discriminate between healthy controls (n = 5) and precancerous mice (n = 5). Color key indicating metabolite abundance. AUC, area under the curve.